Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model.
Carboplatin, efficient cytostatics for cancer therapy, could induce apoptosis and inhibit the growth of vascular endothelium in several tumor cell lines and xenograft models. It has been suggested that the antitumor effect of chemotherapy could be increased by combining it with an antiangiogenesis agent in anticancer strategy. The present study explored the potential to increase the antitumor effect of carboplatin by combining it with thalidomide in mouse 4T1 breast cancer models, and the underlining mechanism was investigated. The systemic administration of carboplatin and thalidomide significantly decreased tumor growth through increased tumor cell apoptosis compared with either control group. Collectively, these findings suggest that combined treatment has shown synergistic suppression in tumor progression according to the analysis. Furthermore, also was observed reduction in number of lung metastases as compared to isolated treatments and increased survival of the animals. The present study may be important in future exploration of the potential application of the combined approach in the treatment of breast cancer.
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: cms.souza@yahoo.com.br.
Cristina Maria
CM
de Souza
Department of pharmacology, laboratory of antitumor substances biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: anacandidaas@yahoo.com.br.
Ana Cândida
AC
Araújo e Silva
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: clarissaferraciolli@yahoo.com.br.
Clarissa
C
de Jesus Ferraciolli
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: giovannavm@ufmg.br.
Giovanna Vieira
GV
Moreira
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: liliane_cunhacampos@hotmail.com.
Liliane Cunha
LC
Campos
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: dcarlosreis@yahoo.com.br.
Diego Carlos
DC
dos Reis
Department of pharmacology, laboratory of antitumor substances biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: miriam.lopes@pq.cnpq.br.
Miriam Teresa Paz
MT
Lopes
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil; Department of physiology and biophysics, laboratory of angiogenesis, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: monicadf@icb.ufmg.br.
Mônica Alves Neves Diniz
MA
Ferreira
Department of physiology and biophysics, laboratory of angiogenesis, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: andrades@icb.ufmg.br.
Silvia Passos
SP
Andrade
Department of general pathology, laboratory of comparative pathology, biological sciences institute, Federal university of Minas Gerais, 486, 31270-901 Belo Horizonte, Minas Gerais, Brazil. Electronic address: cassalig@icb.ufmg.br.
Geovanni Dantas
GD
Cassali
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D016190:Carboplatin / Q000008:administration & dosage; D045744:Cell Line, Tumor; D018450:Disease Progression; D004357:Drug Synergism; D005260:Female; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
D013792:Thalidomide; D016190:Carboplatin
4T1 murine breast cancer model; Carboplatin; Combination therapy; Survival; Thalidomide